Vita Life SciencesASX:VLS 94 EV-to-FCF is 6.48 as of Jun. 25, 2026, which is 53% below its 10-year median of 13.93. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 562 Drug Manufacturers companies, Vita Life Sciences ranks better than 85.94% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vita Life Sciences's Enterprise Value is A$102.69 Mil.
Vita Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$15.86 Mil. Therefore, Vita Life Sciences's EV-to-FCF for today is 6.48.
The historical rank and industry rank for Vita Life Sciences's EV-to-FCF or its related term are showing as below:
ASX:VLS'
s EV-to-FCF Range Over the Past 10 Years
Min: 4.28 Med: 13.93 Max: 32.14
Current: 6.45
During the past 13 years, the highest EV-to-FCF of Vita Life Sciences was 32.14. The lowest was 4.28. And the median was 13.93.
ASX:VLS's EV-to-FCF is ranked better than 85.94% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs ASX:VLS: 6.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vita Life Sciences (ASX:VLS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vita Life Sciences's PE Ratio (TTM) for today is calculated as:
Vita Life Sciences's share price for today is A$2.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.183.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vita Life Sciences EV-to-FCF Related Terms
Vita Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's EV-to-FCF falls into.
Vita Life Sciences's current Enterprise Value is A$102.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$15.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a EV-to-FCF of 6.48 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vita Life Sciences and its competitors. This is 53% below median its historical median of 13.93. Over the past decade, Vita Life Sciences' EV-to-FCF has ranged from 4.28 to 32.14. According to the industry distribution chart, Vita Life Sciences ranks #79 out of 562 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is Vita Life Sciences' EV-to-FCF too high?
Vita Life Sciences' current EV-to-FCF of 6.48 is 53% below median its 10-year median of 13.93. Over the past 10 years, this metric has ranged from a low of 4.28 to a high of 32.14. The Drug Manufacturers industry median EV-to-FCF is 20.16. Vita Life Sciences' value of 6.48 is 67.9% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #79 out of 562 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #79 out of 562 companies for EV-to-FCF. This places Vita Life Sciences in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.16. Vita Life Sciences' value of 6.48 is 67.9% below this benchmark. Historically, Vita Life Sciences' own EV-to-FCF has ranged from 4.28 to 32.14 over the past decade. While the company's 10-year median is 13.93 vs. the industry median of 20.16, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current EV-to-FCF of 6.48 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current EV-to-FCF is 6.48, which is 53% below median its own 10-year median of 13.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current EV-to-FCF is 6.48, which is 53% below median its 10-year median of 13.93 and 67.9% below the Drug Manufacturers industry median of 20.16. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current EV-to-FCF is 6.48 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
EV-to-FCF: 6.48 (53% below median its 10-year median of 13.93)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 67.9% below the Drug Manufacturers median (#79 of 562)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
